N. Mitchell

First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus

J. Soranson, P. Buchan, R. Walley, 2015, Lupus.

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

P. Tak, C. Buckley, V. Zhdan, 2020, The Lancet Rheumatology.

MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study

P. Tak, C. Peterfy, M. Genovese, 2020, The Lancet Rheumatology.

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

G. Burmester, A. Kelman, J. Kay, 2015, Annals of the rheumatic diseases.

OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial

G. Burmester, A. Kelman, J. Kay, 2013 .